Cargando…

Immunotherapy choice and maintenance for generalized myasthenia gravis in China

AIMS: To compare long‐term efficacy and safety of immunotherapeutic strategies as maintenance to prevent disease relapses of generalized myasthenia gravis (MG) in real‐world settings. METHODS: This is a retrospective cohort study on generalized MG conducted in seven major neurological centers across...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chao, Bu, Bitao, Yang, Huan, Wang, Lihua, Liu, Weibin, Duan, Rui‐Sheng, Zhang, Meini, Zeng, Pei, Du, Chen, Yang, Li, Shi, Fu‐Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702233/ https://www.ncbi.nlm.nih.gov/pubmed/33103369 http://dx.doi.org/10.1111/cns.13468

Ejemplares similares

Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis
por: Bi, Zhuajin, et al.
Publicado: (2022)

Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis
por: Bi, Zhuajin, et al.
Publicado: (2023)

Novel Immunotherapies for Myasthenia Gravis
por: Nair, Sruthi S, et al.
Publicado: (2023)

Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis
por: Duan, Weiwei, et al.
Publicado: (2021)

Polymorphisms in drug metabolism genes predict the risk of refractory myasthenia gravis
por: Zhang, Qing, et al.
Publicado: (2022)

Guillain-Barré syndrome associated with myasthenia gravis: Three cases report and a literature review
por: Cao, Yayun, et al.
Publicado: (2019)

Short-term outcome prediction for myasthenia gravis: an explainable machine learning model
por: Zhong, Huahua, et al.
Publicado: (2023)

Comparison of Clinical Manifestations between Patients with Ocular Myasthenia Gravis and Generalized Myasthenia Gravis
por: Roh, Hyun Seok, et al.
Publicado: (2011)

Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China
por: Huang, Xin, et al.
Publicado: (2018)

Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation
por: Zhang, Qing, et al.
Publicado: (2022)

Benefit and danger from immunotherapy in myasthenia gravis
por: Rodolico, Carmelo, et al.
Publicado: (2021)

Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)

To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis
por: Zhou, Qian, et al.
Publicado: (2021)

Upregulation of circ‐FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR‐133/PAX7
por: Lai, Xiaoyin, et al.
Publicado: (2021)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Immunotherapy for ocular myasthenia gravis: an observational study in Japan
por: Narita, Tomoko, et al.
Publicado: (2023)

Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis
por: Duan, Weiwei, et al.
Publicado: (2022)

Long-Term Improvement in a Chinese Cohort of Glucocorticoid-Resistant Childhood-Onset Myasthenia Gravis Patients Treated With Tacrolimus
por: Bi, Zhuajin, et al.
Publicado: (2022)

Initial Repetitive Nerve Stimulation Test Predicts Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

Molecular and clinical relationship between live‐attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis
por: He, Dan, et al.
Publicado: (2018)

Extraocular Muscle Characteristics Related to Myasthenia Gravis Susceptibility
por: Liu, Rui, et al.
Publicado: (2013)

Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Sotalol‐induced generalized and ocular myasthenia gravis
por: Sharifkazemi, Mohammadbagher, et al.
Publicado: (2019)

Association of Smoking and Generalized Manifestations of Myasthenia Gravis
por: Miyazaki, Yusei, et al.
Publicado: (2021)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Zhao, Rui, et al.
Publicado: (2021)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort
por: Bi, Zhuajin, et al.
Publicado: (2022)

Choices and Challenges With Treatment of Myasthenia Gravis in Pregnancy: A Systematic Review
por: Kumar, Lakshya, et al.
Publicado: (2023)

Serological diagnosis of myasthenia gravis and its clinical significance
por: Li, Yi, et al.
Publicado: (2019)

Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset
por: Zhao, Sijia, et al.
Publicado: (2022)

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis
por: de Meel, R. H. P., et al.
Publicado: (2018)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Prognostic factors for conversion to generalization in ocular myasthenia gravis
por: Witthayaweerasak, Juthamat, et al.
Publicado: (2021)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_emduafk31u35oqgf4bl7bmhkh9